Corebridge Financial’s Arbutus Biopharma ABUS Stock Holding History

Corebridge Financial’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-71,572	Closed	-$250K	–	21
2025 Q1	$250K	Sell	71,572 -1,060	-1%	-$3.54K	﹤0.01%	1937
2024 Q4	$238K	Sell	72,632 -5,483	-7%	-$20.2K	﹤0.01%	2081
2024 Q3	$301K	Buy	78,115 +3,076	+4%	+$11.8K	﹤0.01%	1991
2024 Q2	$232K	Buy	+75,039	New	+$225K	﹤0.01%	2100

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BCP

BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Corebridge Financial's ABUS Position: Q2 2025 in Review

Corebridge Financial sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 71,572 shares — an estimated $250K sold.

Corebridge Financial first reported a position in ABUS in Q2 2024 and held it in 4 quarters. The position peaked at $301K in Q3 2024. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

Corebridge Financial reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 71,572 Arbutus Biopharma shares in Q2 2025, an estimated $250K.
Corebridge Financial first reported a position in Arbutus Biopharma in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Arbutus Biopharma position peaked at $301K in Q3 2024.
162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.